186 related articles for article (PubMed ID: 20707716)
1. Immuno-positron emission tomography: shedding light on clinical antibody therapy.
van Dongen GA; Vosjan MJ
Cancer Biother Radiopharm; 2010 Aug; 25(4):375-85. PubMed ID: 20707716
[TBL] [Abstract][Full Text] [Related]
2. Immuno-PET: a navigator in monoclonal antibody development and applications.
van Dongen GA; Visser GW; Lub-de Hooge MN; de Vries EG; Perk LR
Oncologist; 2007 Dec; 12(12):1379-89. PubMed ID: 18165614
[TBL] [Abstract][Full Text] [Related]
3. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
4. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
5. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
6. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
[TBL] [Abstract][Full Text] [Related]
7. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
[TBL] [Abstract][Full Text] [Related]
8. Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
Jauw YW; Menke-van der Houven van Oordt CW; Hoekstra OS; Hendrikse NH; Vugts DJ; Zijlstra JM; Huisman MC; van Dongen GA
Front Pharmacol; 2016; 7():131. PubMed ID: 27252651
[TBL] [Abstract][Full Text] [Related]
9. Designing the magic bullet? The advancement of immuno-PET into clinical use.
Wright BD; Lapi SE
J Nucl Med; 2013 Aug; 54(8):1171-4. PubMed ID: 23908265
[TBL] [Abstract][Full Text] [Related]
10. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.
van Dongen GA; Poot AJ; Vugts DJ
Tumour Biol; 2012 Jun; 33(3):607-15. PubMed ID: 22270450
[TBL] [Abstract][Full Text] [Related]
11.
Jauw YWS; O'Donoghue JA; Zijlstra JM; Hoekstra OS; Menke-van der Houven van Oordt CW; Morschhauser F; Carrasquillo JA; Zweegman S; Pandit-Taskar N; Lammertsma AA; van Dongen GAMS; Boellaard R; Weber WA; Huisman MC
J Nucl Med; 2019 Dec; 60(12):1825-1832. PubMed ID: 31147401
[No Abstract] [Full Text] [Related]
12. The promise of immuno-PET in radioimmunotherapy.
Verel I; Visser GW; van Dongen GA
J Nucl Med; 2005 Jan; 46 Suppl 1():164S-71S. PubMed ID: 15653665
[TBL] [Abstract][Full Text] [Related]
13. Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [
Lumen D; Vugts D; Chomet M; Imlimthan S; Sarparanta M; Vos R; Schreurs M; Verlaan M; Lang PA; Hippeläinen E; Beaino W; Windhorst AD; Airaksinen AJ
Bioconjug Chem; 2022 May; 33(5):956-968. PubMed ID: 35442642
[TBL] [Abstract][Full Text] [Related]
14. Fully Automated
Poot AJ; Adamzek KWA; Windhorst AD; Vosjan MJWD; Kropf S; Wester HJ; van Dongen GAMS; Vugts DJ
J Nucl Med; 2019 May; 60(5):691-695. PubMed ID: 30530830
[TBL] [Abstract][Full Text] [Related]
15. Current Perspectives on
Yoon JK; Park BN; Ryu EK; An YS; Lee SJ
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560337
[No Abstract] [Full Text] [Related]
16. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
17. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.
Vosjan MJ; Perk LR; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
Nat Protoc; 2010 Apr; 5(4):739-43. PubMed ID: 20360768
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunodetection and radioimmunotherapy of head and neck cancer.
Börjesson PK; Postema EJ; de Bree R; Roos JC; Leemans CR; Kairemo KJ; van Dongen GA
Oral Oncol; 2004 Sep; 40(8):761-72. PubMed ID: 15288829
[TBL] [Abstract][Full Text] [Related]
19. 89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied?
Van Dongen GA; Huisman MC; Boellaard R; Harry Hendrikse N; Windhorst AD; Visser GW; Molthoff CF; Vugts DJ
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):18-38. PubMed ID: 25517081
[TBL] [Abstract][Full Text] [Related]
20. The Role of
van Dongen GAMS; Beaino W; Windhorst AD; Zwezerijnen GJC; Oprea-Lager DE; Hendrikse NH; van Kuijk C; Boellaard R; Huisman MC; Vugts DJ
J Nucl Med; 2021 Apr; 62(4):438-445. PubMed ID: 33277395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
